Full-Course ECMO Strategy for Moderate-to-Severe ARDS
Establishment and Evaluation of a Full-Course ECMO Management Strategy for Patients With Moderate-to-Severe ARDS
China faces major challenges in the ECMO management of patients with moderate-to-severe ARDS, including substantial heterogeneity in clinical practice, low weaning success rates, and high complication rates. A key underlying reason is the lack of a standardized full-course management pathway that is applicable to real-world clinical practice in China. This study focuses on the construction and evidence-based evaluation of a precision full-course ECMO management pathway for patients with moderate-to-severe ARDS, aiming to address fragmented care processes and delayed quality improvement.
The study includes three main components. First, multidisciplinary consensus and evidence-based findings will be integrated to develop a standardized management pathway covering the full chain of assessment, initiation, maintenance, weaning, and rehabilitation. Second, a nationwide multicenter real-world study with a before-and-after design will be conducted to systematically evaluate the clinical effectiveness of this pathway in reducing mortality and complications and improving patient outcomes. Third, a closed-loop dynamic optimization system based on "pathway-data-feedback-improvement" will be established. With the support of an intelligent data platform and multidisciplinary review mechanisms, the pathway will be continuously updated and refined.
Through this study, a reproducible, traceable, and evaluable full-course ECMO management strategy is expected to be established. The study will also build a national collaborative research network and support the development of living clinical guidance, promoting the transition of ECMO care in China from experience-based practice toward standardized, homogeneous, and intelligent management, and providing a key technical framework and practical model for improving critical care.
Tutkimuksen yleiskatsaus
Tila
Tila
Ehdot
Ehdot
Interventio / Hoito
Interventio / Hoito
Yksityiskohtainen kuvaus
This study focuses on the establishment, clinical evaluation, and dynamic optimization of a full-course ECMO management pathway for patients with moderate-to-severe ARDS.
First, a standardized full-course ECMO management pathway will be developed based on evidence-based medicine and multidisciplinary collaboration. The pathway will cover the entire clinical process, including assessment of ECMO indications, ECMO initiation, maintenance management, complication prevention and management, ECMO weaning, rehabilitation, and follow-up. The aim is to standardize key clinical decision points and improve the homogeneity of ECMO care across participating centers.
Second, the clinical effectiveness of the full-course ECMO management pathway will be evaluated through a multicenter, real-world, before-and-after clinical study. Patients treated before implementation of the pathway will serve as the control group, while patients treated after implementation will receive care according to the standardized pathway. The study will systematically assess whether implementation of the pathway improves clinical outcomes in patients with moderate-to-severe ARDS receiving ECMO.
Third, a closed-loop system for pathway implementation and dynamic optimization will be established. This system will follow a "pathway-data-feedback-improvement" model. Based on updated guidelines and evidence generated from this study, key intervention points, process key performance indicators, and quality indicators will be defined. A unified electronic pathway and data dictionary will be used across participating centers. Physicians, respiratory therapists, and nurses will record key parameters and reasons for pathway deviations through an intelligent data platform.
Regular multidisciplinary reviews will be conducted monthly or quarterly to evaluate pathway implementation, identify process barriers, analyze center-level variation, and review the root causes of adverse events. Statistical process control, cumulative sum analysis, and risk-adjusted benchmarking may be used to support quality monitoring and continuous improvement. Based on the accumulated clinical data and evidence, living clinical guidance or practice recommendations will be updated iteratively.
The final goal of this study is to establish a reproducible, traceable, and evaluable full-course ECMO management pathway for patients with moderate-to-severe ARDS, thereby supporting standardized and homogeneous ECMO care across multiple centers.
Opintotyyppi
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Ilmoittautuminen
Vaihe
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
Opiskeluyhteys
- Nimi: yingzi Huang, M.D.
- Puhelinnumero: 18271428804
- Sähköposti: yz_huang@126.com
Opiskelupaikat
-
-
-
Beijing, Kiina
- Rekrytointi
- Beijing AnZhen Hospital, Capital Medical University
-
Ottaa yhteyttä:
- Zhongtao Du
-
Changchun, Kiina
- Ei vielä rekrytointia
- The Second Hospital of Jilin University
-
Chengdu, Kiina
- Ei vielä rekrytointia
- West China Tianfu Hospital, Sichuan University
-
Chenzhou, Kiina
- Ei vielä rekrytointia
- The First People's Hospital of Chenzhou
-
Dalian, Kiina
- Rekrytointi
- The Second Affiliated Hospital of Dalian Medical University
-
Fuzhou, Kiina
- Rekrytointi
- Fuzhou University Affiliated Provincial Hospital
-
Ottaa yhteyttä:
- Shang
-
Guangzhou, Kiina
- Rekrytointi
- The First Affiliated Hospital of Guangzhou Medical University
-
Ottaa yhteyttä:
- Yan Wang
-
Hangzhou, Kiina
- Rekrytointi
- The Second Affiliated Hospital of Zhejiang University School of Medicine
-
Ottaa yhteyttä:
- Xie
-
Hangzhou, Kiina
- Ei vielä rekrytointia
- Affiliated Hangzhou First People's Hospital of Westlake University School of Medicine
-
Ha’erbin, Kiina
- Ei vielä rekrytointia
- The First Affiliated Hospital of Harbin Medical University
-
Ha’erbin, Kiina
- Rekrytointi
- The Second Affiliated Hospital of Harbin Medical University
-
Ottaa yhteyttä:
- Hongliang Wang
-
Huai'an, Kiina
- Ei vielä rekrytointia
- Huai'an first people's hospital
-
Jinan, Kiina
- Rekrytointi
- Qilu Hospital of Shandong University
-
Ottaa yhteyttä:
- Hao Wang
-
Kunshan, Kiina
- Ei vielä rekrytointia
- The First People's Hospital of Kunshan
-
Lanzhou, Kiina
- Ei vielä rekrytointia
- The First Hospital of Lanzhou University
-
Lianyungang, Kiina
- Ei vielä rekrytointia
- The first people's hospital of Lianyungang
-
Liuzhou, Kiina
- Rekrytointi
- Liuzhou People's Hospital
-
Ottaa yhteyttä:
- Wenfang Jiang
-
Nanjing, Kiina
- Ei vielä rekrytointia
- Jiangsu Province Hospital
-
Nanjing, Kiina
- Rekrytointi
- Zhongda Hospital Southeast University
-
Ottaa yhteyttä:
- Xiaojing Wu
- Puhelinnumero: 13951876234
- Sähköposti: 36410257@qq.com
-
Nanjing, Kiina
- Rekrytointi
- Nanjing Drum Tower Hospital (The Affiliated Hospital of Nanjing University Medical School)
-
Ottaa yhteyttä:
- Danjiang Dong
-
Nanning, Kiina
- Ei vielä rekrytointia
- The People's Hospital of Guangxi Zhuang Autonomous Region
-
Nanning, Kiina
- Ei vielä rekrytointia
- The First Affiliated Hospital of Guangxi Medical University
-
Nanning, Kiina
- Ei vielä rekrytointia
- The Second Affiliated Hospital of Guangxi Medical University
-
Nantong, Kiina
- Ei vielä rekrytointia
- Affiliated Hospital of Nantong University
-
Ningxiang, Kiina
- Ei vielä rekrytointia
- General Hospital of Ningxia Medical University
-
Qinghai, Kiina
- Ei vielä rekrytointia
- The Affiliated Hospital of Qinghai University
-
Quzhou, Kiina
- Rekrytointi
- Quzhou people's Hospital
-
Sichuan, Kiina
- Rekrytointi
- Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital (SAMS&SPPH, Affiliated Hospital of UESTC)
-
Ottaa yhteyttä:
- Hongli He
-
Suining, Kiina
- Ei vielä rekrytointia
- Suining Central Hospital
-
Suzhou, Kiina
- Ei vielä rekrytointia
- The First Affiliated Hospital of Soochow University
-
Wuxi, Kiina
- Rekrytointi
- Wuxi People's Hospital
-
Ottaa yhteyttä:
- Hongyang Xu
-
Xi'an, Kiina
- Rekrytointi
- The Second Affiliated Hospital of Xi'an Jiaotong University
-
Ottaa yhteyttä:
- jing Geng
-
Xiamen, Kiina
- Ei vielä rekrytointia
- The First Affiliated Hospital of Xiamen University
-
Xinyang, Kiina
- Ei vielä rekrytointia
- Xinyang Central Hospital
-
Xuzhou, Kiina
- Ei vielä rekrytointia
- The Affiliated Hospital of Xuzhou Medical Universit
-
Yangzhou, Kiina
- Ei vielä rekrytointia
- Northern Jiangsu People's Hospital
-
Zhengzhou, Kiina
- Rekrytointi
- Henan Provincial People's Hospital
-
Ottaa yhteyttä:
- Huanzhang Shao
-
Zhengzhou, Kiina
- Ei vielä rekrytointia
- The First Affiliated Hospital of Zhengzhou University
-
Zhongshan, Kiina
- Ei vielä rekrytointia
- Zhongshan Hospital of Traditional Chinese Medicine
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Kuvaus
Inclusion Criteria:
- 1. Age 18 years or older. 2. Diagnosed with moderate-to-severe acute respiratory distress syndrome according to the global definition of ARDS.
Exclusion Criteria:
- 1. Patients with tracheostomy before screening. 2. Patients who have received lung transplantation or are receiving venovenous extracorporeal membrane oxygenation as a bridge to lung transplantation.
3. Patients with cardiogenic shock requiring venoarterial ECMO or venoarterial-venous ECMO support.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Ei satunnaistettu
- Inventiomalli: Peräkkäinen tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseiden lukumäärä
Aseet ja interventiot
Osallistujaryhmä / ArmOsallistujaryhmä / Arm |
Interventio / HoitoInterventio / Hoito |
|---|---|
|
Muut: Pre-Implementation Usual Care
Participants in this arm are patients with moderate-to-severe ARDS who received ECMO before implementation of the standardized full-course ECMO management pathway.
Clinical care will be provided according to usual practice at each participating center, including ECMO initiation, maintenance, complication management, weaning, and rehabilitation based on local protocols and clinician judgment.
|
Usual care refers to ECMO management provided before implementation of the standardized full-course ECMO management pathway.
Clinical decisions are made according to local practice and clinician judgment at each participating center.
|
|
Kokeellinen: Post-Implementation ECMO Management Pathway
Participants in this arm are patients with moderate-to-severe ARDS who receive ECMO after implementation of the standardized full-course ECMO management pathway.
Clinical care will follow the pathway covering assessment of ECMO indications, ECMO initiation, maintenance management, complication prevention and management, weaning assessment, rehabilitation, and follow-up.
Individualized adjustments are allowed according to patient condition, and pathway deviations will be recorded.
|
The intervention is a standardized full-course ECMO management pathway for patients with moderate-to-severe ARDS.
The pathway covers assessment of ECMO indications, ECMO initiation, cannulation and anticoagulation strategies, mechanical ventilation management, hemodynamic and fluid management, infection prevention, analgesia and sedation, nutrition and rehabilitation, complication prevention and management, weaning assessment, discharge, and follow-up.
Individualized adjustments are allowed according to patient condition, and pathway deviations will be recorded for quality improvement and subsequent analysis.
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
|---|---|
|
90-Day All-Cause Mortality
Aikaikkuna: From ECMO initiation to 90 days after ECMO initiation
|
From ECMO initiation to 90 days after ECMO initiation
|
Toissijaiset tulostoimenpiteet
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
28-Day All-Cause Mortality
Aikaikkuna: 28 days after ECMO initiation
|
The proportion of participants who die from any cause within 28 days after ECMO initiation will be compared between the pre-implementation usual care group and the post-implementation ECMO management pathway group.
|
28 days after ECMO initiation
|
|
Successful Liberation From Mechanical Ventilation
Aikaikkuna: From initiation of invasive mechanical ventilation to 7 days after liberation from mechanical ventilation, assessed up to hospital discharge
|
Successful liberation from mechanical ventilation is defined as survival without reintubation or death within 7 days after extubation in patients without tracheostomy, or survival without reconnection to mechanical ventilation or death within 7 days afte
|
From initiation of invasive mechanical ventilation to 7 days after liberation from mechanical ventilation, assessed up to hospital discharge
|
|
ICU Mortality
Aikaikkuna: From ICU admission to ICU discharge or death, assessed up to 90 days after ECMO initiation
|
The proportion of participants who die during the ICU stay will be compared between the pre-implementation usual care group and the post-implementation ECMO management pathway group.
|
From ICU admission to ICU discharge or death, assessed up to 90 days after ECMO initiation
|
|
ICU Length of Stay
Aikaikkuna: From ICU admission to ICU discharge, assessed up to 90 days after ECMO initiation
|
ICU length of stay is defined as the number of days from ICU admission to ICU discharge or death.
|
From ICU admission to ICU discharge, assessed up to 90 days after ECMO initiation
|
|
Respiratory Support at ICU Discharge
Aikaikkuna: At ICU discharge, assessed up to 90 days after ECMO initiation
|
Respiratory support status at ICU discharge will be recorded, including tracheostomy, invasive mechanical ventilation, noninvasive ventilation or high-flow nasal cannula, conventional oxygen therapy, or no oxygen therapy.
|
At ICU discharge, assessed up to 90 days after ECMO initiation
|
|
Hospital Mortality
Aikaikkuna: From hospital admission to hospital discharge or death, assessed up to 90 days after ECMO initiation
|
The proportion of participants who die during hospitalization will be compared between the pre-implementation usual care group and the post-implementation ECMO management pathway group.
|
From hospital admission to hospital discharge or death, assessed up to 90 days after ECMO initiation
|
|
Hospital Length of Stay
Aikaikkuna: From hospital admission to hospital discharge, assessed up to 90 days after ECMO initiation
|
Hospital length of stay is defined as the number of days from hospital admission to hospital discharge or death.
|
From hospital admission to hospital discharge, assessed up to 90 days after ECMO initiation
|
|
Respiratory Support at Hospital Discharge
Aikaikkuna: At hospital discharge, assessed up to 90 days after ECMO initiation
|
Respiratory support status at hospital discharge will be recorded, including tracheostomy, invasive mechanical ventilation, noninvasive ventilation or high-flow nasal cannula, conventional oxygen therapy, or no oxygen therapy.
|
At hospital discharge, assessed up to 90 days after ECMO initiation
|
|
Incidence of ECMO-Related Complications
Aikaikkuna: From ECMO initiation to 48 hours after ECMO decannulation
|
The incidence of ECMO-related complications will be compared between the pre-implementation usual care group and the post-implementation ECMO management pathway group.
ECMO-related complications include major bleeding, minor bleeding, mechanical or circuit thrombosis, patient-related thrombosis, hospital-acquired infection during ECMO, hemolysis, cannulation-related complications, acute kidney injury, and oxygenator replacement.
|
From ECMO initiation to 48 hours after ECMO decannulation
|
|
Major Bleeding Events
Aikaikkuna: From ECMO initiation to 48 hours after ECMO decannulation
|
Major bleeding is defined as bleeding that meets at least one of the following criteria: life-threatening bleeding, including intracranial bleeding, retroperitoneal bleeding, cardiac tamponade, or bleeding leading to hemorrhagic shock; bleeding requiring surgical intervention; or transfusion of at least 2 units of red blood cells within 24 hours due to active bleeding.
|
From ECMO initiation to 48 hours after ECMO decannulation
|
|
Minor Bleeding Events
Aikaikkuna: From ECMO initiation to ECMO decannulation
|
Mechanical or circuit thrombosis is defined as thrombus formation observed or diagnosed within the extracorporeal circuit during ECMO support, including thrombosis in the ECMO oxygenator, pump head, tubing, connectors, or other circuit components.
|
From ECMO initiation to ECMO decannulation
|
|
Patient-Related Thrombotic Events
Aikaikkuna: From ECMO initiation to 48 hours after ECMO decannulation
|
Patient-related thrombotic events are defined as thrombotic or embolic events occurring within the patient's vascular system and confirmed by clinical findings, imaging, or autopsy.
Events include deep vein thrombosis, pulmonary embolism, and ischemic stroke.
|
From ECMO initiation to 48 hours after ECMO decannulation
|
|
Hospital-Acquired Infection During ECMO
Aikaikkuna: From 24 hours after ECMO initiation to 48 hours after ECMO decannulation
|
Hospital-acquired infection during ECMO is defined as infection occurring more than 24 hours after ECMO initiation and up to 48 hours after ECMO decannulation.
Infection sites include bloodstream infection, respiratory tract infection or ventilator-associated pneumonia, mediastinitis, cannulation-site or surgical-site infection, urinary tract infection, or other documented infection sites.
|
From 24 hours after ECMO initiation to 48 hours after ECMO decannulation
|
|
Hemolysis During ECMO
Aikaikkuna: From ECMO initiation to ECMO decannulation
|
Hemolysis is defined as plasma-free hemoglobin greater than 500 mg/L, equivalent to greater than 50 mg/dL, after ECMO cannulation.
|
From ECMO initiation to ECMO decannulation
|
|
Cannulation-Related Complications
Aikaikkuna: From ECMO cannulation to 48 hours after ECMO decannulation
|
Cannulation-related complications include limb ischemia, pseudoaneurysm, arteriovenous fistula, vascular dissection, or other vascular complications related to ECMO cannulation.
Limb ischemia is defined as impaired distal perfusion of the cannulated limb requiring clinical evaluation or intervention.
|
From ECMO cannulation to 48 hours after ECMO decannulation
|
|
Acute Kidney Injury During ECMO
Aikaikkuna: From ECMO initiation to ECMO decannulation
|
Acute kidney injury during ECMO will be assessed according to KDIGO criteria and classified as stage 1, stage 2, or stage 3.
The need for continuous renal replacement therapy will also be recorded.
|
From ECMO initiation to ECMO decannulation
|
|
Oxygenator Replacement
Aikaikkuna: From ECMO initiation to ECMO decannulation
|
Oxygenator replacement is defined as replacement of the ECMO oxygenator for any reason during ECMO support, including oxygenator thrombosis, gas exchange dysfunction, increased transmembrane pressure, hemolysis, or other clinical indications.
|
From ECMO initiation to ECMO decannulation
|
Yhteistyökumppanit ja tutkijat
Sponsori
Sponsori
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Opiskelun aloitus
Ensisijainen valmistuminen (Arvioitu)
Ensisijainen valmistuminen
Opintojen valmistuminen (Arvioitu)
Opintojen valmistuminen
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Ensimmäinen Lähetetty
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin päivitys julkaistu
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
Muut tutkimustunnusnumerot
- 2026ZDSYLL081-P01
- 2026ZD0555505 (Muu apuraha/rahoitusnumero: National Key R&D Program of China)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .